EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury

Mahyar Khazaeli iD, Ane C F Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D Vaziri, Bhupinder Singh, Wei Ling Lau iD

Pharmacology Research & Perspectives · 2023

DOI: 10.1002/prp2.1079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Mahyar Khazaeli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, University at Buffalo, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tetrahydrocurcumin (THC), a principal metabolite of curcumin, was tested in a rat model of type 2 diabetes mellitus. THC was administered via daily oral gavage with the lipid carrier polyenylphosphatidylcholine (PPC) as add‐on therapy to losartan (angiotensin receptor blocker) to examine effects on kidney oxidative stress and fibrosis. A combination of unilateral nephrectomy, high‐fat diet and low‐dose streptozotocin was used to induce diabetic nephropathy in male Sprague–Dawley rats. Animals with fasting blood glucose >200 mg/dL were randomized to PPC, losartan, THC + PPC or THC + PPC + losartan. Untreated chronic kidney disease (CKD) animals had proteinuria, decreased creatinine clearance, and evidence of kidney fibrosis on histology. THC + PPC + losartan treatment significantly lowered blood pressure concurrent with increased messenger RNA levels of antioxidant copper‐zinc‐superoxide dismutase and decreased protein kinase C‐α, kidney injury molecule‐1 and type I collagen in the kidneys; there was decreased albuminuria and a trend for increased creatinine clearance compared to untreated CKD rats. There was decreased fibrosis on kidney histology in PPC‐only and THC‐treated CKD rats. Plasma levels of kidney injury molecule‐1 were decreased in THC + PPC + losartan animals. In summary, add‐on THC to losartan therapy improved antioxidant levels and decreased fibrosis in the kidneys, and lowered blood pressure in diabetic CKD rats.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic NephropathiesRenal Insufficiency, ChronicAnimalsMaleRatsAntioxidantsBlood PressureCreatinineFibrosisKidneyLosartanRats, Sprague-DawleyCurcumin

Stichwörter der Autor:innen

animal modelschronic kidney diseasesdiabetic nephropathylosartanproteinuriatetrahydrocurcumin

Substanzen

AntioxidantsCreatinineLosartantetrahydrocurcuminCurcumin

Autor:innen und Institutionen

  • Pathology Department, University at Buffalo, Buffalo, New York, USA.
  • Division of Nephrology, Department of Medicine, University of California, Irvine, California, USA.

ORCID-Profile: Mahyar Khazaeli, Wei Ling Lau

Zitieren

APA

Khazaeli, M., Nunes, A. C. F., Zhao, Y., Khazaali, M., Prudente, J., Vaziri, N. D., Singh, B., & Lau, W. L. (2023). Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1079

Vancouver

Khazaeli M, Nunes ACF, Zhao Y, Khazaali M, Prudente J, Vaziri ND, et al. Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1079

BibTeX
@article{Khazaeli2023,
  author = {Khazaeli, Mahyar and Nunes, Ane C F and Zhao, Yitong and Khazaali, Mahziar and Prudente, John and Vaziri, Nosratola D and Singh, Bhupinder and Lau, Wei Ling},
  title = {Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury},
  journal = {Pharmacology Research & Perspectives},
  year = {2023},
  doi = {10.1002/prp2.1079}
}
Kostenlos starten →